aTyr Pharma refocuses efzofitimod Phase 3 strategy on lung function after failed steroid endpoint
aTyr Pharma gains FDA alignment for a new efzofitimod Phase 3 trial in pulmonary sarcoidosis after the earlier EFZO-FIT endpoint miss.
Pharma & Biotech